📣 VC round data is live. Check it out!

iRadimed Valuation Multiples

Discover revenue and EBITDA valuation multiples for iRadimed and similar public comparables like Medartis, Alphatec Holdings, Inspire Medical Systems, Avanos Medical and more.

iRadimed Overview

About iRadimed

iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.


Founded

1992

HQ

United States

Employees

160

Financials (LTM)

Revenue: $87M
EBITDA: $29M

EV

$1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

iRadimed Financials

iRadimed reported last 12-month revenue of $87M and EBITDA of $29M.

In the same LTM period, iRadimed generated $66M in gross profit, $29M in EBITDA, and $23M in net income.

Revenue (LTM)


iRadimed P&L

In the most recent fiscal year, iRadimed reported revenue of $84M and EBITDA of $27M.

iRadimed is profitable as of last fiscal year, with gross margin of 77%, EBITDA margin of 33%, and net margin of 27%.

See analyst estimates for iRadimed
LTMLast FY202320242025202620272028
Revenue$87M$84M$66M$73M$84M
Gross Profit$66M$64M$50M$56M$64M
Gross Margin76%77%77%77%77%
EBITDA$29M$27M$21M$23M$27M
EBITDA Margin33%33%32%31%33%
EBIT Margin32%31%31%30%31%
Net Profit$23M$22M$17M$19M$22M
Net Margin27%27%26%26%27%

Financial data powered by Morningstar, Inc.

iRadimed Stock Performance

iRadimed has current market cap of $1B, and enterprise value of $1B.

Market Cap Evolution


iRadimed's stock price is $89.86.

iRadimed share price decreased by 1.1% in the last 30 days, and increased by 50.3% in the last year.

iRadimed has an EPS (earnings per share) of $1.76.

See more trading valuation data for iRadimed
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1B$1B-2.2%-1.1%-6.6%50.3%$1.76

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

iRadimed Valuation Multiples

iRadimed trades at 12.6x EV/Revenue multiple, and 37.8x EV/EBITDA.

See NTM and 2027E valuation multiples for iRadimed

EV / Revenue (LTM)


iRadimed Financial Valuation Multiples

As of June 3, 2026, iRadimed has market cap of $1B and EV of $1B.

iRadimed has a P/E ratio of 49.2x.

LTMLast FY202320242025202620272028
EV/Revenue12.6x13.1x16.7x15.0x13.1x
EV/EBITDA37.8x40.2x52.8x48.2x40.2x
EV/EBIT39.6x42.0x54.8x50.0x42.0x
EV/Gross Profit16.5x17.1x21.9x19.5x17.1x
P/E49.2x51.1x66.8x59.7x51.1x
EV/FCF64.4x66.4x201.1x65.3x66.4x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified iRadimed Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

iRadimed Margins & Growth Rates

iRadimed grew revenue by 9% and EBITDA by 15% in the last fiscal year.

In the most recent fiscal year, iRadimed reported gross margin of 77%, EBITDA margin of 33%, and net margin of 27%.

See estimated margins and future growth rates for iRadimed

iRadimed Margins

Last FY202420252026202720282029
Gross Margin77%77%77%76%
EBITDA Margin33%31%33%34%
EBIT Margin31%30%31%33%
Net Margin27%26%27%27%
FCF Margin20%23%20%20%

iRadimed Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth9%12%14%9%
Gross Profit Growth8%12%14%8%
EBITDA Growth15%10%20%15%
EBIT Growth14%10%19%14%
Net Profit Growth9%12%17%9%
FCF Growth8%208%(2%)8%

Data powered by FactSet, Inc. and Morningstar, Inc.

iRadimed Operational KPIs

iRadimed's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.

iRadimed's Rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

iRadimed's Rule of X is 56% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for iRadimed
LTMLast FY202320242025202620272028
Rule of 4043%43%---
Bessemer Rule of X57%56%---
Revenue per Employee-$0.5M---
Opex per Employee-$0.2M---
S&M Expenses to Revenue21%21%19%21%21%
G&A Expenses to Revenue21%21%23%22%21%
R&D Expenses to Revenue4%4%4%4%4%
Opex to Revenue-46%46%47%46%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

iRadimed Competitors

iRadimed competitors include Medartis, Alphatec Holdings, Inspire Medical Systems, Avanos Medical, Butterfly Network, Shinva, Integra Lifesciences, Arcs Co, Curiox Biosystems and Mani Inc..

Most iRadimed public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Medartis3.8x3.5x22.5x21.3x
Alphatec Holdings2.1x2.0x17.3x14.6x
Inspire Medical Systems1.0x1.0x4.5x4.8x
Avanos Medical1.8x1.8x14.3x14.0x
Butterfly Network11.1x10.1x(40.7x)(43.1x)
Shinva0.6x0.6x7.1x7.1x
Integra Lifesciences1.8x1.8x9.5x9.3x
Arcs Co0.2x0.2x3.7x3.8x

This data is available for Pro users. Sign up to see all iRadimed competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About iRadimed

When was iRadimed founded?iRadimed was founded in 1992.
Where is iRadimed headquartered?iRadimed is headquartered in United States.
How many employees does iRadimed have?As of today, iRadimed has over 160 employees.
Who is the CEO of iRadimed?iRadimed's CEO is Roger Susi.
Is iRadimed publicly listed?Yes, iRadimed is a public company listed on Nasdaq.
What is the stock symbol of iRadimed?iRadimed trades under IRMD ticker.
When did iRadimed go public?iRadimed went public in 2014.
Who are competitors of iRadimed?iRadimed main competitors include Medartis, Alphatec Holdings, Inspire Medical Systems, Avanos Medical, Butterfly Network, Shinva, Integra Lifesciences, Arcs Co, Curiox Biosystems, Mani Inc..
What is the current market cap of iRadimed?iRadimed's current market cap is $1B.
What is the current revenue of iRadimed?iRadimed's last 12 months revenue is $87M.
What is the current revenue growth of iRadimed?iRadimed revenue growth (NTM/LTM) is 10%.
What is the current EV/Revenue multiple of iRadimed?Current revenue multiple of iRadimed is 12.6x.
What is the current EBITDA of iRadimed?iRadimed's last 12 months EBITDA is $29M.
What is iRadimed's EBITDA margin?iRadimed's last 12 months EBITDA margin is 33%.
What is the current EV/EBITDA multiple of iRadimed?Current EBITDA multiple of iRadimed is 37.8x.
What is the current FCF of iRadimed?iRadimed's last 12 months FCF is $17M.
What is iRadimed's FCF margin?iRadimed's last 12 months FCF margin is 20%.
What is the current EV/FCF multiple of iRadimed?Current FCF multiple of iRadimed is 64.4x.
How many companies iRadimed has acquired to date?iRadimed hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies iRadimed has invested to date?iRadimed hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to iRadimed

Lists including iRadimed

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial